ASX - By Stock
|
PEN |
Re:
PEN Short Squeeze
|
|
Serpentis
|
141 |
73K |
4 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
141
|
73K
|
4
|
|
ASX - By Stock
|
PEN |
Re:
PEN Short Squeeze
|
|
Serpentis
|
141 |
73K |
13 |
13/01/24 |
13/01/24 |
ASX - By Stock
|
141
|
73K
|
13
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
37 |
06/10/22 |
06/10/22 |
ASX - By Stock
|
5.1K
|
2.4M
|
37
|
|
ASX - By Stock
|
GLN |
Re:
General Discussion Banter GLN
|
|
Serpentis
|
16K |
6.4M |
10 |
02/10/22 |
02/10/22 |
ASX - By Stock
|
16K
|
6.4M
|
10
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Expansion and Acceleration of Clinical Programs
|
|
Serpentis
|
70 |
27K |
24 |
27/09/22 |
27/09/22 |
ASX - By Stock
|
70
|
27K
|
24
|
|
ASX - By Stock
|
AKE |
Re:
Ann: Allkem to acquire lithium tenement in exchange for Borax
|
|
Serpentis
|
21 |
14K |
18 |
15/08/22 |
15/08/22 |
ASX - By Stock
|
21
|
14K
|
18
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
1 |
14/08/22 |
14/08/22 |
ASX - By Stock
|
5.1K
|
2.4M
|
1
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
4 |
14/08/22 |
14/08/22 |
ASX - By Stock
|
5.1K
|
2.4M
|
4
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
38 |
28/07/22 |
28/07/22 |
ASX - By Stock
|
5.1K
|
2.4M
|
38
|
|
ASX - By Stock
|
AKE |
Re:
AKE Chart
|
|
Serpentis
|
5.8K |
2.4M |
4 |
02/03/22 |
02/03/22 |
ASX - By Stock
|
5.8K
|
2.4M
|
4
|
|
ASX - By Stock
|
AKE |
Re:
Ann: FY22 Half Year Results Presentation
|
|
Serpentis
|
55 |
27K |
26 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
55
|
27K
|
26
|
|
ASX - By Stock
|
GLN |
Re:
Compelling opportunity
|
|
Serpentis
|
5.9K |
1.8M |
17 |
21/01/22 |
21/01/22 |
ASX - By Stock
|
5.9K
|
1.8M
|
17
|
|
ASX - By Stock
|
AKE |
Re:
Ann: December Quarterly Activities Report
|
|
Serpentis
|
80 |
37K |
52 |
18/01/22 |
18/01/22 |
ASX - By Stock
|
80
|
37K
|
52
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
2 |
10/12/21 |
10/12/21 |
ASX - By Stock
|
5.1K
|
2.4M
|
2
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
4 |
09/12/21 |
09/12/21 |
ASX - By Stock
|
5.1K
|
2.4M
|
4
|
|
ASX - By Stock
|
AKE |
Re:
Allkem General Discussion
|
|
Serpentis
|
5.1K |
2.4M |
15 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
5.1K
|
2.4M
|
15
|
|
ASX - By Stock
|
AKE |
Re:
Ann: Change of Company Name and Ticker
|
|
Serpentis
|
62 |
23K |
6 |
06/12/21 |
06/12/21 |
ASX - By Stock
|
62
|
23K
|
6
|
|
ASX - By Stock
|
AKE |
Re:
Ann: September Quarterly Report
|
|
Serpentis
|
107 |
37K |
17 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
107
|
37K
|
17
|
|
ASX - By Stock
|
AKE |
Re:
Ann: September Quarterly Report
|
|
Serpentis
|
107 |
37K |
44 |
22/10/21 |
22/10/21 |
ASX - By Stock
|
107
|
37K
|
44
|
|
ASX - By Stock
|
AKE |
Re:
ORE Chart
|
|
Serpentis
|
2.5K |
1.1M |
18 |
21/10/21 |
21/10/21 |
ASX - By Stock
|
2.5K
|
1.1M
|
18
|
|
ASX - By Stock
|
AKE Lithium |
Re:
EV and battery thread
|
|
Serpentis
|
2.5K |
871K |
37 |
19/10/21 |
19/10/21 |
ASX - By Stock
|
2.5K
|
871K
|
37
|
|
ASX - By Stock
|
AKE |
Re:
Banter and General Comments
|
|
Serpentis
|
647 |
250K |
14 |
15/10/21 |
15/10/21 |
ASX - By Stock
|
647
|
250K
|
14
|
|
ASX - By Stock
|
KLL |
Re:
Ann: Trading Halt
|
|
Serpentis
|
157 |
47K |
9 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
157
|
47K
|
9
|
|
ASX - By Stock
|
KLL |
Re:
Ann: Trading Halt
|
|
Serpentis
|
157 |
47K |
10 |
13/10/21 |
13/10/21 |
ASX - By Stock
|
157
|
47K
|
10
|
|
ASX - By Stock
|
AKE |
Re:
Banter and General Comments
|
|
Serpentis
|
647 |
250K |
29 |
11/10/21 |
11/10/21 |
ASX - By Stock
|
647
|
250K
|
29
|
|
ASX - By Stock
|
AKE |
Re:
ORE Chart
|
|
Serpentis
|
2.5K |
1.1M |
27 |
07/10/21 |
07/10/21 |
ASX - By Stock
|
2.5K
|
1.1M
|
27
|
|
ASX - By Stock
|
AKE |
Re:
Banter and General Comments
|
|
Serpentis
|
647 |
250K |
28 |
02/10/21 |
02/10/21 |
ASX - By Stock
|
647
|
250K
|
28
|
|
ASX - By Stock
|
AKE |
Re:
Banter and General Comments
|
|
Serpentis
|
647 |
250K |
11 |
02/10/21 |
02/10/21 |
ASX - By Stock
|
647
|
250K
|
11
|
|
ASX - By Stock
|
AKE |
Re:
Banter and General Comments
|
|
Serpentis
|
647 |
250K |
37 |
01/10/21 |
01/10/21 |
ASX - By Stock
|
647
|
250K
|
37
|
|
ASX - By Stock
|
AKE |
Re:
Ann: FY21 Results Presentation
|
|
Serpentis
|
104 |
35K |
19 |
25/08/21 |
25/08/21 |
ASX - By Stock
|
104
|
35K
|
19
|
|
ASX - By Stock
|
GXY |
Re:
TA - Short Term Trading
|
|
Serpentis
|
1.8K |
532K |
1 |
06/08/21 |
06/08/21 |
ASX - By Stock
|
1.8K
|
532K
|
1
|
|
ASX - By Stock
|
GXY |
Re:
TA - Short Term Trading
|
|
Serpentis
|
1.8K |
532K |
34 |
06/08/21 |
06/08/21 |
ASX - By Stock
|
1.8K
|
532K
|
34
|
|
ASX - By Stock
|
GXY |
Re:
Ann: Scheme Booklet registered by ASIC
|
|
Serpentis
|
76 |
30K |
8 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
76
|
30K
|
8
|
|
ASX - By Stock
|
GXY |
Re:
Ann: Scheme Booklet registered by ASIC
|
|
Serpentis
|
76 |
30K |
23 |
05/07/21 |
05/07/21 |
ASX - By Stock
|
76
|
30K
|
23
|
|
ASX - By Stock
|
GXY |
Re:
Ann: Orocobre and Galaxy Merger - Announcement
|
|
Serpentis
|
694 |
299K |
4 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
694
|
299K
|
4
|
|
ASX - By Stock
|
GXY |
Re:
Ann: Orocobre and Galaxy Merger - Announcement
|
|
Serpentis
|
694 |
299K |
78 |
22/04/21 |
22/04/21 |
ASX - By Stock
|
694
|
299K
|
78
|
|
ASX - By Stock
|
GXY |
Re:
What ORE brings to the table
|
|
Serpentis
|
12 |
5.2K |
47 |
21/04/21 |
21/04/21 |
ASX - By Stock
|
12
|
5.2K
|
47
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Sinusitis Patient Update - Special Access Scheme
|
|
Serpentis
|
140 |
32K |
21 |
07/04/21 |
07/04/21 |
ASX - By Stock
|
140
|
32K
|
21
|
|
ASX - By Stock
|
KLL |
Re:
Project update?
|
|
Serpentis
|
376 |
128K |
6 |
10/03/21 |
10/03/21 |
ASX - By Stock
|
376
|
128K
|
6
|
|
ASX - By Stock
|
KLL |
Re:
Ann: Quarterly Cashflow Report
|
|
Serpentis
|
201 |
55K |
6 |
18/02/21 |
18/02/21 |
ASX - By Stock
|
201
|
55K
|
6
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Fiona Stanley Hospital Phase I/II Clinical Trial Agreement
|
|
Serpentis
|
33 |
8.3K |
9 |
16/02/21 |
16/02/21 |
ASX - By Stock
|
33
|
8.3K
|
9
|
|
ASX - By Stock
|
KLL |
Re:
Ann: Quarterly Cashflow Report
|
|
Serpentis
|
201 |
55K |
5 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
201
|
55K
|
5
|
|
ASX - By Stock
|
KLL |
Re:
Ann: Quarterly Cashflow Report
|
|
Serpentis
|
201 |
55K |
15 |
29/01/21 |
29/01/21 |
ASX - By Stock
|
201
|
55K
|
15
|
|
ASX - By Stock
|
RCE Biotech |
Re:
RCE Charts
|
|
Serpentis
|
2.1K |
650K |
0 |
08/01/21 |
08/01/21 |
ASX - By Stock
|
2.1K
|
650K
|
0
|
|
ASX - By Stock
|
TYP Biotech |
Re:
Codiak ($800mil market capitalisation)
|
|
Serpentis
|
183 |
56K |
7 |
04/01/21 |
04/01/21 |
ASX - By Stock
|
183
|
56K
|
7
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Intranasal Animal Data against SARS-CoV-2 in Study
|
|
Serpentis
|
48 |
13K |
1 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
48
|
13K
|
1
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Intranasal Animal Data against SARS-CoV-2 in Study
|
|
Serpentis
|
48 |
13K |
14 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
48
|
13K
|
14
|
|
ASX - By Stock
|
RCE |
Re:
Ann: Positive Intranasal Animal Data against SARS-CoV-2 in Study
|
|
Serpentis
|
48 |
13K |
16 |
23/12/20 |
23/12/20 |
ASX - By Stock
|
48
|
13K
|
16
|
|
ASX - By Stock
|
KLL |
Re:
News: KLL Kalium Lakes Ltd Says Overall Beyondie Sop Project Is 75% Complete
|
|
Serpentis
|
61 |
16K |
3 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
61
|
16K
|
3
|
|
ASX - By Stock
|
KLL |
Re:
News: KLL Kalium Lakes Ltd Says Overall Beyondie Sop Project Is 75% Complete
|
|
Serpentis
|
61 |
16K |
3 |
19/12/20 |
19/12/20 |
ASX - By Stock
|
61
|
16K
|
3
|
|